These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 23295790)
21. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Wynne J; Wright D; Stock W Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147 [TBL] [Abstract][Full Text] [Related]
22. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083 [TBL] [Abstract][Full Text] [Related]
23. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703 [TBL] [Abstract][Full Text] [Related]
24. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K; Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007 [TBL] [Abstract][Full Text] [Related]
26. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412 [TBL] [Abstract][Full Text] [Related]
27. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. Foss FM; Parker T Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091 [TBL] [Abstract][Full Text] [Related]
28. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155 [TBL] [Abstract][Full Text] [Related]
29. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582 [TBL] [Abstract][Full Text] [Related]
30. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611 [TBL] [Abstract][Full Text] [Related]
31. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611 [TBL] [Abstract][Full Text] [Related]
32. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231 [TBL] [Abstract][Full Text] [Related]
33. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842 [TBL] [Abstract][Full Text] [Related]
34. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004 [TBL] [Abstract][Full Text] [Related]
35. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467 [TBL] [Abstract][Full Text] [Related]